BASTIDE LE CONFORT MEDICAL (BLC.PA) Fundamental Analysis & Valuation

EPA:BLC • FR0000035370

Current stock price

23.725 EUR
+0.43 (+1.82%)
Last:

This BLC.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BLC.PA Profitability Analysis

1.1 Basic Checks

  • BLC had positive earnings in the past year.
  • In the past year BLC had a positive cash flow from operations.
  • BLC had positive earnings in 4 of the past 5 years.
  • BLC had a positive operating cash flow in each of the past 5 years.
BLC.PA Yearly Net Income VS EBIT VS OCF VS FCFBLC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 5.07%, BLC belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
  • BLC has a better Return On Equity (28.66%) than 100.00% of its industry peers.
  • BLC's Return On Invested Capital of 6.83% is fine compared to the rest of the industry. BLC outperforms 75.86% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BLC is in line with the industry average of 5.99%.
  • The last Return On Invested Capital (6.83%) for BLC is above the 3 year average (6.14%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 5.07%
ROE 28.66%
ROIC 6.83%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
BLC.PA Yearly ROA, ROE, ROICBLC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • BLC's Profit Margin of 6.19% is amongst the best of the industry. BLC outperforms 93.10% of its industry peers.
  • In the last couple of years the Profit Margin of BLC has declined.
  • The Operating Margin of BLC (8.05%) is better than 62.07% of its industry peers.
  • BLC's Operating Margin has been stable in the last couple of years.
  • BLC's Gross Margin of 67.32% is fine compared to the rest of the industry. BLC outperforms 72.41% of its industry peers.
  • BLC's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 8.05%
PM (TTM) 6.19%
GM 67.32%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
BLC.PA Yearly Profit, Operating, Gross MarginsBLC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. BLC.PA Health Analysis

2.1 Basic Checks

  • BLC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for BLC remains at a similar level compared to 1 year ago.
  • BLC has about the same amout of shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BLC has been reduced compared to a year ago.
BLC.PA Yearly Shares OutstandingBLC.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
BLC.PA Yearly Total Debt VS Total AssetsBLC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • BLC has an Altman-Z score of 1.52. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of BLC (1.52) is comparable to the rest of the industry.
  • The Debt to FCF ratio of BLC is 14.03, which is on the high side as it means it would take BLC, 14.03 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 14.03, BLC is doing worse than 62.07% of the companies in the same industry.
  • BLC has a Debt/Equity ratio of 2.95. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 2.95, BLC is doing worse than 72.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.95
Debt/FCF 14.03
Altman-Z 1.52
ROIC/WACC1.3
WACC5.26%
BLC.PA Yearly LT Debt VS Equity VS FCFBLC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 1.16 indicates that BLC should not have too much problems paying its short term obligations.
  • BLC's Current ratio of 1.16 is in line compared to the rest of the industry. BLC outperforms 58.62% of its industry peers.
  • BLC has a Quick Ratio of 1.16. This is a bad value and indicates that BLC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BLC has a Quick ratio (0.92) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 0.92
BLC.PA Yearly Current Assets VS Current LiabilitesBLC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BLC.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 1718.18% over the past year.
  • The earnings per share for BLC have been decreasing by -46.37% on average. This is quite bad
  • BLC shows a small growth in Revenue. In the last year, the Revenue has grown by 0.77%.
  • Measured over the past years, BLC shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)1718.18%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%4912.5%
Revenue 1Y (TTM)0.77%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%-5.5%

3.2 Future

  • Based on estimates for the next years, BLC will show a small growth in Earnings Per Share. The EPS will grow by 5.90% on average per year.
  • The Revenue is expected to grow by 7.69% on average over the next years.
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLC.PA Yearly Revenue VS EstimatesBLC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BLC.PA Yearly EPS VS EstimatesBLC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

6

4. BLC.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • BLC is valuated cheaply with a Price/Earnings ratio of 5.93.
  • BLC's Price/Earnings ratio is rather cheap when compared to the industry. BLC is cheaper than 96.55% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BLC to the average of the S&P500 Index (25.35), we can say BLC is valued rather cheaply.
  • A Price/Forward Earnings ratio of 11.58 indicates a reasonable valuation of BLC.
  • BLC's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BLC is cheaper than 72.41% of the companies in the same industry.
  • BLC is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.61, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 5.93
Fwd PE 11.58
BLC.PA Price Earnings VS Forward Price EarningsBLC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 93.10% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, BLC is valued a bit cheaper than 68.97% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.57
EV/EBITDA 4.83
BLC.PA Per share dataBLC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • The decent profitability rating of BLC may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.23%
EPS Next 3Y5.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLC.PA Dividend Analysis

5.1 Amount

  • BLC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLC.PA Fundamentals: All Metrics, Ratios and Statistics

BASTIDE LE CONFORT MEDICAL

EPA:BLC (4/1/2026, 10:25:48 AM)

23.725

+0.43 (+1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-18
Earnings (Next)05-14
Inst Owners12.76%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap174.85M
Revenue(TTM)476.02M
Net Income(TTM)29.45M
Analysts77.14
Price Target40.8 (71.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP0.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.68%
PT rev (3m)11.11%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.26%
EPS NY rev (3m)-26.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.26%
Valuation
Industry RankSector Rank
PE 5.93
Fwd PE 11.58
P/S 0.37
P/FCF 7.57
P/OCF 2.42
P/B 1.7
P/tB N/A
EV/EBITDA 4.83
EPS(TTM)4
EY16.86%
EPS(NY)2.05
Fwd EY8.64%
FCF(TTM)3.13
FCFY13.21%
OCF(TTM)9.79
OCFY41.26%
SpS64.59
BVpS13.94
TBVpS-12.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number35.42
Profitability
Industry RankSector Rank
ROA 5.07%
ROE 28.66%
ROCE 9.29%
ROIC 6.83%
ROICexc 7.28%
ROICexgc 14.48%
OM 8.05%
PM (TTM) 6.19%
GM 67.32%
FCFM 4.85%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 2.95
Debt/FCF 14.03
Debt/EBITDA 3.11
Cap/Depr 83.01%
Cap/Sales 10.3%
Interest Coverage 250
Cash Conversion 74.08%
Profit Quality 78.46%
Current Ratio 1.16
Quick Ratio 0.92
Altman-Z 1.52
F-Score7
WACC5.26%
ROIC/WACC1.3
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1718.18%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%4912.5%
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue 1Y (TTM)0.77%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%-5.5%
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%
EBIT growth 1Y3.06%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year138.04%
EBIT Next 3Y38.82%
EBIT Next 5YN/A
FCF growth 1Y-31.71%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y-17.98%
OCF growth 3Y17.38%
OCF growth 5Y14.21%

BASTIDE LE CONFORT MEDICAL / BLC.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a fundamental rating of 5 / 10 to BLC.PA.


Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a valuation rating of 6 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.


What is the profitability of BLC stock?

BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for BLC stock?

The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 5.93 and the Price/Book (PB) ratio is 1.7.


Can you provide the financial health for BLC stock?

The financial health rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 2 / 10.